Candel Therapeutics (CADL) Net Cash Flow (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Net Cash Flow data on file, last reported at $32.9 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 61.77% year-over-year to $32.9 million; the trailing twelve-month figure through Dec 2025 stood at $17.2 million (down 74.38% YoY), and the FY2025 full-year result was $17.2 million, down 74.38% from the prior year.
• Net Cash Flow advanced to $32.9 million in Q4 2025, from -$13.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $86.1 million in Q4 2024 to a low of -$13.7 million in Q3 2025.
• A 5-year average of $4.2 million and a median of -$6.4 million in 2021 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 2964.06% in 2021 and tumbled 192.37% in 2023, its largest moves.
• Tracing CADL's Net Cash Flow over 5 years: stood at -$5.7 million in 2021, then dropped by 24.09% to -$7.1 million in 2022, then retreated by 6.25% to -$7.6 million in 2023, then surged by 1237.33% to $86.1 million in 2024, then tumbled by 61.77% to $32.9 million in 2025.
• Business Quant data shows CADL's Net Cash Flow at $32.9 million in Q4 2025, -$13.7 million in Q3 2025, and $8.5 million in Q2 2025.